Quick Answer
Oric Pharmaceuticals, Inc. reported Net Income of -$129.47 million for fiscal year 2025.
Oric Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$129.47M -1.3% |
-$127.85M -27.0% |
-$100.70M -13.0% |
-$89.12M -13.2% |
-$78.72M -6.8% |
-$73.70M -174.2% |
| Diluted EPS | -$1.47 +19.7% |
-$1.83 +6.6% |
-$1.96 +12.9% |
-$2.25 -8.7% |
-$2.07 | — |
| Total Assets | $408.89M +49.2% |
$274.14M +8.8% |
$252.01M +2.0% |
$247.18M -17.2% |
$298.64M -0.1% |
$299.00M +217.8% |
| Cash and Equivalents | $45.67M -23.1% |
$59.41M +154.0% |
$23.38M -65.0% |
$66.84M -70.4% |
$226.01M +188.1% |
$78.45M -12.0% |
| Stockholders Equity | $384.36M +58.1% |
$243.12M +8.5% |
$224.09M +0.8% |
$222.35M -18.5% |
$272.98M -5.8% |
$289.78M +421.7% |
| Operating Income | -$143.00M -0.1% |
-$142.90M -29.0% |
-$110.78M -20.7% |
-$91.77M -16.4% |
-$78.87M -6.3% |
-$74.19M -159.7% |
| Shares Outstanding | 98.53M +38.7% |
71.02M +29.4% |
54.87M +21.7% |
45.09M +14.4% |
39.43M +7.5% |
36.67M +1748.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$32.59M | +5.7% | +10.4% |
| Diluted EPS | September 30, 2025 | -$0.33 | +32.7% | +29.8% |
| Total Assets | September 30, 2025 | $431.19M | +42.7% | +24.3% |
| Cash and Equivalents | September 30, 2025 | $49.67M | +12.3% | -34.5% |
| Stockholders Equity | September 30, 2025 | $406.92M | +48.5% | +25.6% |
| R&D Expense | June 30, 2020 | $7.72M | +53.2% | +6.5% |
| Operating Income | September 30, 2025 | -$36.67M | +4.3% | +6.1% |
| Shares Outstanding | September 30, 2025 | 97.28M | +37.9% | +12.9% |
- Oric Pharmaceuticals, Inc. reported Net Income of -$129.47 million for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed a decrease of -1.3% in Net Income compared to the prior fiscal year.
- Oric Pharmaceuticals, Inc. reported Diluted EPS of $1.47 per share (loss) for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed an increase of +19.7% in Diluted EPS compared to the prior fiscal year.
- Oric Pharmaceuticals, Inc. reported Total Assets of $408.89 million for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed an increase of +49.2% in Total Assets compared to the prior fiscal year.
- Oric Pharmaceuticals, Inc. reported Cash and Equivalents of $45.67 million for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed a decrease of -23.1% in Cash and Equivalents compared to the prior fiscal year.
- Oric Pharmaceuticals, Inc. reported Stockholders Equity of $384.36 million for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed an increase of +58.1% in Stockholders Equity compared to the prior fiscal year.
- Oric Pharmaceuticals, Inc. reported Operating Income of -$143.00 million for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed a decrease of -0.1% in Operating Income compared to the prior fiscal year.
- Oric Pharmaceuticals, Inc. reported Shares Outstanding of 98.53 million shares for fiscal year 2025.
- Oric Pharmaceuticals, Inc. showed an increase of +38.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: